Peter Sartipy
AstraZeneca (Sweden)(SE)
Publications by Year
Research Areas
Pluripotent Stem Cells Research, 3D Printing in Biomedical Research, CRISPR and Genetic Engineering, Tissue Engineering and Regenerative Medicine, Diabetes Treatment and Management
Most-Cited Works
- → Monocyte chemoattractant protein 1 in obesity and insulin resistance(2003)1,192 cited
- → Genomic alterations in cultured human embryonic stem cells(2005)622 cited
- → Human embryonic stem cells have a unique epigenetic signature(2006)271 cited
- → Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study(2018)184 cited
- → Localization of Nonpancreatic Secretory Phospholipase A 2 in Normal and Atherosclerotic Arteries(1997)171 cited
- → Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study ( US , UK and Sweden)(2021)158 cited
- → Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: Possible contribution of phospholipase A2 to this atherogenic profile(2001)138 cited
- → Application of human stem cell-derived cardiomyocytes in safety pharmacology requires caution beyond hERG(2012)137 cited
- → Phospholipase A2 Modification of Low Density Lipoproteins Forms Small High Density Particles with Increased Affinity for Proteoglycans and Glycosaminoglycans(1999)119 cited
- → Differentiation of Human Embryonic Stem Cells to Cardiomyocytes for In Vitro and In Vivo Applications(2010)112 cited